APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Thrombin Inhibitors (DTIs)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Direct Thrombin Inhibitors (DTIs) Industry Growth and Trends Forecast to 2032

28 December 2025126 pages

Choose your research edition.

Industry ResearchDirect Thrombin Inhibitors (DTIs) Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Thrombin Inhibitors (DTIs) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Direct Thrombin Inhibitors (DTIs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Thrombin Inhibitors (DTIs) Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Thrombin Inhibitors (DTIs) Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Direct Thrombin Inhibitors (DTIs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Thrombin Inhibitors (DTIs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Direct Thrombin Inhibitors (DTIs) include Accord Healthcare, Amneal Pharms, Apotex, Boehringer Ingelheim, Dr.Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, GlaxoSmithKline and Hikma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Direct Thrombin Inhibitors (DTIs) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Direct Thrombin Inhibitors (DTIs) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Direct Thrombin Inhibitors (DTIs) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Direct Thrombin Inhibitors (DTIs).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Direct Thrombin Inhibitors (DTIs) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Direct Thrombin Inhibitors (DTIs) Market by Company

Accord Healthcare

Amneal Pharms

Apotex

Boehringer Ingelheim

Dr.Reddy's Laboratories

Eugia Pharma

Fresenius Kabi

GlaxoSmithKline

Hikma

Mitsubishi Tanabe Pharma

MSN

Pfizer

Sandoz

Teva Pharmaceutical

The Medicines Company

Beijing Baiao Pharmaceutical

BrightGene

Chengdu Brilliant Pharmaceutical

Hainan Poly Pharm

Hainan Shuangcheng Pharmaceuticals

Hansoh Pharma

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Yangtze River Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Direct Thrombin Inhibitors (DTIs) Segment by Type

Oral DTIs

Parenteral DTIs

Direct Thrombin Inhibitors (DTIs) Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Thrombocytopenia

Other

Direct Thrombin Inhibitors (DTIs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Thrombin Inhibitors (DTIs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Thrombin Inhibitors (DTIs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Thrombin Inhibitors (DTIs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Direct Thrombin Inhibitors (DTIs) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Direct Thrombin Inhibitors (DTIs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral DTIs Table 2. Major Company of Parenteral DTIs Table 3. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 5. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type (2021-2026) Table 6. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (US$ Million) Table 7. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type (2021-2026) Table 8. Global Direct Thrombin Inhibitors (DTIs) Price by Type (2021-2026) & (US$/Unit) Table 9. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2027-2032) & (K Units) Table 10. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type (2027-2032) Table 11. Global Direct Thrombin Inhibitors (DTIs) Sales by Type (2027-2032) & (US$ Million) Table 12. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type (2027-2032) Table 13. Global Direct Thrombin Inhibitors (DTIs) Price by Type (2027-2032) & (US$/Unit) Table 14. North America Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 15. North America Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 17. Europe Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 21. Latin America Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Type (2021-2026) & (US$ Million) Table 24. Direct Thrombin Inhibitors (DTIs) Industry Trends Table 25. Direct Thrombin Inhibitors (DTIs) Industry Drivers Table 26. Direct Thrombin Inhibitors (DTIs) Industry Opportunities and Challenges Table 27. Direct Thrombin Inhibitors (DTIs) Industry Restraints Table 28. Global Direct Thrombin Inhibitors (DTIs) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Direct Thrombin Inhibitors (DTIs) Revenue Market Share by Company (2021-2026) Table 30. Global Direct Thrombin Inhibitors (DTIs) Sales by Company (2021-2026) & (K Units) Table 31. Global Direct Thrombin Inhibitors (DTIs) Sales Share by Company (2021-2026) Table 32. Global Direct Thrombin Inhibitors (DTIs) Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Direct Thrombin Inhibitors (DTIs) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Direct Thrombin Inhibitors (DTIs) Major Company Production Sites and Headquarters Table 35. Global Direct Thrombin Inhibitors (DTIs) Company, Product Type & Application Table 36. Global Direct Thrombin Inhibitors (DTIs) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Direct Thrombin Inhibitors (DTIs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Direct Thrombin Inhibitors (DTIs) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2021-2026) & (K Units) Table 41. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Region (2021-2026) Table 42. Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2021-2026) & (US$ Million) Table 43. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Region (2021-2026) Table 44. Global Direct Thrombin Inhibitors (DTIs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2027-2032) & (K Units) Table 46. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Region (2027-2032) Table 47. Global Direct Thrombin Inhibitors (DTIs) Sales by Region (2027-2032) & (US$ Million) Table 48. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Region (2027-2032) Table 49. Global Direct Thrombin Inhibitors (DTIs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 52. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application (2021-2026) Table 53. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (US$ Million) Table 54. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application (2021-2026) Table 55. Global Direct Thrombin Inhibitors (DTIs) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2027-2032) & (K Units) Table 57. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application (2027-2032) Table 58. Global Direct Thrombin Inhibitors (DTIs) Sales by Application (2027-2032) & (US$ Million) Table 59. Global Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application (2027-2032) Table 60. Global Direct Thrombin Inhibitors (DTIs) Price by Application (2027-2032) & (US$/Unit) Table 61. North America Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 62. North America Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 64. Europe Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 68. Latin America Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Application (2021-2026) & (US$ Million) Table 71. Accord Healthcare Company Information Table 72. Accord Healthcare Business Overview Table 73. Accord Healthcare Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Accord Healthcare Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 75. Accord Healthcare Recent Development Table 76. Amneal Pharms Company Information Table 77. Amneal Pharms Business Overview Table 78. Amneal Pharms Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Amneal Pharms Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 80. Amneal Pharms Recent Development Table 81. Apotex Company Information Table 82. Apotex Business Overview Table 83. Apotex Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Apotex Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 85. Apotex Recent Development Table 86. Boehringer Ingelheim Company Information Table 87. Boehringer Ingelheim Business Overview Table 88. Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 90. Boehringer Ingelheim Recent Development Table 91. Dr.Reddy's Laboratories Company Information Table 92. Dr.Reddy's Laboratories Business Overview Table 93. Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 95. Dr.Reddy's Laboratories Recent Development Table 96. Eugia Pharma Company Information Table 97. Eugia Pharma Business Overview Table 98. Eugia Pharma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Eugia Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 100. Eugia Pharma Recent Development Table 101. Fresenius Kabi Company Information Table 102. Fresenius Kabi Business Overview Table 103. Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 105. Fresenius Kabi Recent Development Table 106. GlaxoSmithKline Company Information Table 107. GlaxoSmithKline Business Overview Table 108. GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 110. GlaxoSmithKline Recent Development Table 111. Hikma Company Information Table 112. Hikma Business Overview Table 113. Hikma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Hikma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 115. Hikma Recent Development Table 116. Mitsubishi Tanabe Pharma Company Information Table 117. Mitsubishi Tanabe Pharma Business Overview Table 118. Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 120. Mitsubishi Tanabe Pharma Recent Development Table 121. MSN Company Information Table 122. MSN Business Overview Table 123. MSN Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. MSN Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 125. MSN Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Pfizer Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 130. Pfizer Recent Development Table 131. Sandoz Company Information Table 132. Sandoz Business Overview Table 133. Sandoz Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Sandoz Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 135. Sandoz Recent Development Table 136. Teva Pharmaceutical Company Information Table 137. Teva Pharmaceutical Business Overview Table 138. Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 140. Teva Pharmaceutical Recent Development Table 141. The Medicines Company Company Information Table 142. The Medicines Company Business Overview Table 143. The Medicines Company Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. The Medicines Company Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 145. The Medicines Company Recent Development Table 146. Beijing Baiao Pharmaceutical Company Information Table 147. Beijing Baiao Pharmaceutical Business Overview Table 148. Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 150. Beijing Baiao Pharmaceutical Recent Development Table 151. BrightGene Company Information Table 152. BrightGene Business Overview Table 153. BrightGene Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. BrightGene Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 155. BrightGene Recent Development Table 156. Chengdu Brilliant Pharmaceutical Company Information Table 157. Chengdu Brilliant Pharmaceutical Business Overview Table 158. Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 160. Chengdu Brilliant Pharmaceutical Recent Development Table 161. Hainan Poly Pharm Company Information Table 162. Hainan Poly Pharm Business Overview Table 163. Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 165. Hainan Poly Pharm Recent Development Table 166. Hainan Shuangcheng Pharmaceuticals Company Information Table 167. Hainan Shuangcheng Pharmaceuticals Business Overview Table 168. Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 170. Hainan Shuangcheng Pharmaceuticals Recent Development Table 171. Hansoh Pharma Company Information Table 172. Hansoh Pharma Business Overview Table 173. Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 175. Hansoh Pharma Recent Development Table 176. Lunan Pharmaceutical Company Information Table 177. Lunan Pharmaceutical Business Overview Table 178. Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 180. Lunan Pharmaceutical Recent Development Table 181. Qilu Pharmaceutical Company Information Table 182. Qilu Pharmaceutical Business Overview Table 183. Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 185. Qilu Pharmaceutical Recent Development Table 186. CSPC Ouyi Pharmaceutical Company Information Table 187. CSPC Ouyi Pharmaceutical Business Overview Table 188. CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 189. CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 190. CSPC Ouyi Pharmaceutical Recent Development Table 191. Yangtze River Pharmaceutical Company Information Table 192. Yangtze River Pharmaceutical Business Overview Table 193. Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 194. Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 195. Yangtze River Pharmaceutical Recent Development Table 196. Chia Tai Tianqing Pharmaceutical Company Information Table 197. Chia Tai Tianqing Pharmaceutical Business Overview Table 198. Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 199. Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio Table 200. Chia Tai Tianqing Pharmaceutical Recent Development Table 201. North America Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 202. North America Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 203. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2026) Table 204. North America Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032) & (K Units) Table 205. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share Forecast by Country (2027-2032) Table 206. North America Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. North America Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026) & (US$ Million) Table 208. North America Direct Thrombin Inhibitors (DTIs) Market Share by Country (2021-2026) Table 209. North America Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. North America Direct Thrombin Inhibitors (DTIs) Market Share Forecast by Country (2027-2032) Table 211. Europe Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 212. Europe Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 213. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2026) Table 214. Europe Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032) & (K Units) Table 215. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share Forecast by Country (2027-2032) Table 216. Europe Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 217. Europe Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026) & (US$ Million) Table 218. Europe Direct Thrombin Inhibitors (DTIs) Market Share by Country (2021-2026) Table 219. Europe Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 220. Europe Direct Thrombin Inhibitors (DTIs) Market Share Forecast by Country (2027-2032) Table 221. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 222. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 223. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2026) Table 224. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032) & (K Units) Table 225. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share Forecast by Country (2027-2032) Table 226. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 227. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026) & (US$ Million) Table 228. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Share by Country (2021-2026) Table 229. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 230. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Share Forecast by Country (2027-2032) Table 231. Latin America Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 232. Latin America Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 233. Latin America Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2026) Table 234. Latin America Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032) & (K Units) Table 235. Latin America Direct Thrombin Inhibitors (DTIs) Sales Market Share Forecast by Country (2027-2032) Table 236. Latin America Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 237. Latin America Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026) & (US$ Million) Table 238. Latin America Direct Thrombin Inhibitors (DTIs) Market Share by Country (2021-2026) Table 239. Latin America Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 240. Latin America Direct Thrombin Inhibitors (DTIs) Market Share Forecast by Country (2027-2032) Table 241. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 242. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026) & (K Units) Table 243. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share by Country (2021-2026) Table 244. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032) & (K Units) Table 245. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share Forecast by Country (2027-2032) Table 246. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 247. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026) & (US$ Million) Table 248. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Share by Country (2021-2026) Table 249. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 250. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Share Forecast by Country (2027-2032) Table 251. Key Raw Materials Table 252. Raw Materials Key Suppliers Table 253. Direct Thrombin Inhibitors (DTIs) Distributors List Table 254. Direct Thrombin Inhibitors (DTIs) Customers List Table 255. Research Programs/Design for This Report Table 256. Authors List of This Report Table 257. Secondary Sources Table 258. Primary Sources List of Figures Figure 1. Direct Thrombin Inhibitors (DTIs) Image Figure 2. Global Direct Thrombin Inhibitors (DTIs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Thrombin Inhibitors (DTIs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Direct Thrombin Inhibitors (DTIs) Sales (2021-2032) & (K Units) Figure 5. Oral DTIs Image Figure 6. Global Oral DTIs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Parenteral DTIs Image Figure 8. Global Parenteral DTIs Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Direct Thrombin Inhibitors (DTIs) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Direct Thrombin Inhibitors (DTIs) Market Share by Type 2025 VS 2032 Figure 11. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type in 2025 Figure 12. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type in 2025 Figure 13. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type in 2025 Figure 14. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type in 2025 Figure 17. Latin America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Direct Thrombin Inhibitors (DTIs) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Pulmonary Embolism Image Figure 24. Global Pulmonary Embolism Sales YoY Growth (2021-2032) & (K Units) Figure 25. Deep Vein Thrombosis Image Figure 26. Global Deep Vein Thrombosis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Atrial Fibrillation Image Figure 28. Global Atrial Fibrillation Sales YoY Growth (2021-2032) & (K Units) Figure 29. Thrombocytopenia Image Figure 30. Global Thrombocytopenia Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Direct Thrombin Inhibitors (DTIs) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Direct Thrombin Inhibitors (DTIs) Market Share by Application 2025 VS 2032 Figure 35. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application in 2025 Figure 36. North America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application in 2025 Figure 37. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application in 2025 Figure 38. Europe Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application in 2025 Figure 41. Latin America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Market Share in Value by Application in 2025 Figure 45. North America Direct Thrombin Inhibitors (DTIs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Direct Thrombin Inhibitors (DTIs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Direct Thrombin Inhibitors (DTIs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Direct Thrombin Inhibitors (DTIs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Direct Thrombin Inhibitors (DTIs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Direct Thrombin Inhibitors (DTIs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Direct Thrombin Inhibitors (DTIs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Direct Thrombin Inhibitors (DTIs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Direct Thrombin Inhibitors (DTIs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Direct Thrombin Inhibitors (DTIs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Direct Thrombin Inhibitors (DTIs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Direct Thrombin Inhibitors (DTIs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Direct Thrombin Inhibitors (DTIs) Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Direct Thrombin Inhibitors (DTIs) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oral DTIs
  • Parenteral DTIs
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Thrombocytopenia
  • Other
Companies covered
  • Accord Healthcare
  • Amneal Pharms
  • Apotex
  • Boehringer Ingelheim
  • Dr.Reddy's Laboratories
  • Eugia Pharma
  • Fresenius Kabi
  • GlaxoSmithKline
  • Hikma
  • Mitsubishi Tanabe Pharma
  • MSN
  • Pfizer
  • Sandoz
  • Teva Pharmaceutical
  • The Medicines Company
  • Beijing Baiao Pharmaceutical
  • BrightGene
  • Chengdu Brilliant Pharmaceutical
  • Hainan Poly Pharm
  • Hainan Shuangcheng Pharmaceuticals
  • Hansoh Pharma
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Yangtze River Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Direct Thrombin Inhibitors (DTIs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Direct Thrombin Inhibitors (DTIs) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Direct Thrombin Inhibitors (DTIs) Market by Type
  6. 1.3.1 Oral DTIs
  7. 1.3.2 Parenteral DTIs
  8. 1.4 Global Direct Thrombin Inhibitors (DTIs) Market Size by Type
  9. 1.4.1 Global Direct Thrombin Inhibitors (DTIs) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Direct Thrombin Inhibitors (DTIs) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Direct Thrombin Inhibitors (DTIs) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Direct Thrombin Inhibitors (DTIs) Industry Trends
  2. 2.2 Direct Thrombin Inhibitors (DTIs) Industry Drivers
  3. 2.3 Direct Thrombin Inhibitors (DTIs) Industry Opportunities and Challenges
  4. 2.4 Direct Thrombin Inhibitors (DTIs) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Direct Thrombin Inhibitors (DTIs) Revenue (2021-2026)
  2. 3.2 Global Top Players by Direct Thrombin Inhibitors (DTIs) Sales (2021-2026)
  3. 3.3 Global Top Players by Direct Thrombin Inhibitors (DTIs) Price (2021-2026)
  4. 3.4 Global Direct Thrombin Inhibitors (DTIs) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Direct Thrombin Inhibitors (DTIs) Major Company Production Sites & Headquarters
  6. 3.6 Global Direct Thrombin Inhibitors (DTIs) Company, Product Type & Application
  7. 3.7 Global Direct Thrombin Inhibitors (DTIs) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Direct Thrombin Inhibitors (DTIs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Direct Thrombin Inhibitors (DTIs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Direct Thrombin Inhibitors (DTIs) Tier 1, Tier 2, and Tier 3
4 Direct Thrombin Inhibitors (DTIs) Regional Status and Outlook
  1. 4.1 Global Direct Thrombin Inhibitors (DTIs) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Direct Thrombin Inhibitors (DTIs) Historic Market Size by Region
  3. 4.2.1 Global Direct Thrombin Inhibitors (DTIs) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Direct Thrombin Inhibitors (DTIs) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Direct Thrombin Inhibitors (DTIs) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Direct Thrombin Inhibitors (DTIs) Forecasted Market Size by Region
  7. 4.3.1 Global Direct Thrombin Inhibitors (DTIs) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Direct Thrombin Inhibitors (DTIs) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Direct Thrombin Inhibitors (DTIs) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Direct Thrombin Inhibitors (DTIs) by Application
  1. 5.1 Direct Thrombin Inhibitors (DTIs) Market by Application
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Thrombocytopenia
  6. 5.1.5 Other
  7. 5.2 Global Direct Thrombin Inhibitors (DTIs) Market Size by Application
  8. 5.2.1 Global Direct Thrombin Inhibitors (DTIs) Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Direct Thrombin Inhibitors (DTIs) Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Direct Thrombin Inhibitors (DTIs) Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Accord Healthcare
  2. 6.1.1 Accord Healthcare Company Information
  3. 6.1.2 Accord Healthcare Business Overview
  4. 6.1.3 Accord Healthcare Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Accord Healthcare Direct Thrombin Inhibitors (DTIs) Product Portfolio
  6. 6.1.5 Accord Healthcare Recent Developments
  7. 6.2 Amneal Pharms
  8. 6.2.1 Amneal Pharms Company Information
  9. 6.2.2 Amneal Pharms Business Overview
  10. 6.2.3 Amneal Pharms Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Amneal Pharms Direct Thrombin Inhibitors (DTIs) Product Portfolio
  12. 6.2.5 Amneal Pharms Recent Developments
  13. 6.3 Apotex
  14. 6.3.1 Apotex Company Information
  15. 6.3.2 Apotex Business Overview
  16. 6.3.3 Apotex Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Apotex Direct Thrombin Inhibitors (DTIs) Product Portfolio
  18. 6.3.5 Apotex Recent Developments
  19. 6.4 Boehringer Ingelheim
  20. 6.4.1 Boehringer Ingelheim Company Information
  21. 6.4.2 Boehringer Ingelheim Business Overview
  22. 6.4.3 Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Boehringer Ingelheim Direct Thrombin Inhibitors (DTIs) Product Portfolio
  24. 6.4.5 Boehringer Ingelheim Recent Developments
  25. 6.5 Dr.Reddy's Laboratories
  26. 6.5.1 Dr.Reddy's Laboratories Company Information
  27. 6.5.2 Dr.Reddy's Laboratories Business Overview
  28. 6.5.3 Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Dr.Reddy's Laboratories Direct Thrombin Inhibitors (DTIs) Product Portfolio
  30. 6.5.5 Dr.Reddy's Laboratories Recent Developments
  31. 6.6 Eugia Pharma
  32. 6.6.1 Eugia Pharma Company Information
  33. 6.6.2 Eugia Pharma Business Overview
  34. 6.6.3 Eugia Pharma Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eugia Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  36. 6.6.5 Eugia Pharma Recent Developments
  37. 6.7 Fresenius Kabi
  38. 6.7.1 Fresenius Kabi Company Information
  39. 6.7.2 Fresenius Kabi Business Overview
  40. 6.7.3 Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Fresenius Kabi Direct Thrombin Inhibitors (DTIs) Product Portfolio
  42. 6.7.5 Fresenius Kabi Recent Developments
  43. 6.8 GlaxoSmithKline
  44. 6.8.1 GlaxoSmithKline Company Information
  45. 6.8.2 GlaxoSmithKline Business Overview
  46. 6.8.3 GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 GlaxoSmithKline Direct Thrombin Inhibitors (DTIs) Product Portfolio
  48. 6.8.5 GlaxoSmithKline Recent Developments
  49. 6.9 Hikma
  50. 6.9.1 Hikma Company Information
  51. 6.9.2 Hikma Business Overview
  52. 6.9.3 Hikma Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Hikma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  54. 6.9.5 Hikma Recent Developments
  55. 6.10 Mitsubishi Tanabe Pharma
  56. 6.10.1 Mitsubishi Tanabe Pharma Company Information
  57. 6.10.2 Mitsubishi Tanabe Pharma Business Overview
  58. 6.10.3 Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Mitsubishi Tanabe Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  60. 6.10.5 Mitsubishi Tanabe Pharma Recent Developments
  61. 6.11 MSN
  62. 6.11.1 MSN Company Information
  63. 6.11.2 MSN Business Overview
  64. 6.11.3 MSN Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 MSN Direct Thrombin Inhibitors (DTIs) Product Portfolio
  66. 6.11.5 MSN Recent Developments
  67. 6.12 Pfizer
  68. 6.12.1 Pfizer Company Information
  69. 6.12.2 Pfizer Business Overview
  70. 6.12.3 Pfizer Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Pfizer Direct Thrombin Inhibitors (DTIs) Product Portfolio
  72. 6.12.5 Pfizer Recent Developments
  73. 6.13 Sandoz
  74. 6.13.1 Sandoz Company Information
  75. 6.13.2 Sandoz Business Overview
  76. 6.13.3 Sandoz Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sandoz Direct Thrombin Inhibitors (DTIs) Product Portfolio
  78. 6.13.5 Sandoz Recent Developments
  79. 6.14 Teva Pharmaceutical
  80. 6.14.1 Teva Pharmaceutical Company Information
  81. 6.14.2 Teva Pharmaceutical Business Overview
  82. 6.14.3 Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Teva Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  84. 6.14.5 Teva Pharmaceutical Recent Developments
  85. 6.15 The Medicines Company
  86. 6.15.1 The Medicines Company Company Information
  87. 6.15.2 The Medicines Company Business Overview
  88. 6.15.3 The Medicines Company Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 The Medicines Company Direct Thrombin Inhibitors (DTIs) Product Portfolio
  90. 6.15.5 The Medicines Company Recent Developments
  91. 6.16 Beijing Baiao Pharmaceutical
  92. 6.16.1 Beijing Baiao Pharmaceutical Company Information
  93. 6.16.2 Beijing Baiao Pharmaceutical Business Overview
  94. 6.16.3 Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Beijing Baiao Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  96. 6.16.5 Beijing Baiao Pharmaceutical Recent Developments
  97. 6.17 BrightGene
  98. 6.17.1 BrightGene Company Information
  99. 6.17.2 BrightGene Business Overview
  100. 6.17.3 BrightGene Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 BrightGene Direct Thrombin Inhibitors (DTIs) Product Portfolio
  102. 6.17.5 BrightGene Recent Developments
  103. 6.18 Chengdu Brilliant Pharmaceutical
  104. 6.18.1 Chengdu Brilliant Pharmaceutical Company Information
  105. 6.18.2 Chengdu Brilliant Pharmaceutical Business Overview
  106. 6.18.3 Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Chengdu Brilliant Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  108. 6.18.5 Chengdu Brilliant Pharmaceutical Recent Developments
  109. 6.19 Hainan Poly Pharm
  110. 6.19.1 Hainan Poly Pharm Company Information
  111. 6.19.2 Hainan Poly Pharm Business Overview
  112. 6.19.3 Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Hainan Poly Pharm Direct Thrombin Inhibitors (DTIs) Product Portfolio
  114. 6.19.5 Hainan Poly Pharm Recent Developments
  115. 6.20 Hainan Shuangcheng Pharmaceuticals
  116. 6.20.1 Hainan Shuangcheng Pharmaceuticals Company Information
  117. 6.20.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  118. 6.20.3 Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Hainan Shuangcheng Pharmaceuticals Direct Thrombin Inhibitors (DTIs) Product Portfolio
  120. 6.20.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
  121. 6.21 Hansoh Pharma
  122. 6.21.1 Hansoh Pharma Company Information
  123. 6.21.2 Hansoh Pharma Business Overview
  124. 6.21.3 Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Hansoh Pharma Direct Thrombin Inhibitors (DTIs) Product Portfolio
  126. 6.21.5 Hansoh Pharma Recent Developments
  127. 6.22 Lunan Pharmaceutical
  128. 6.22.1 Lunan Pharmaceutical Company Information
  129. 6.22.2 Lunan Pharmaceutical Business Overview
  130. 6.22.3 Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Lunan Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  132. 6.22.5 Lunan Pharmaceutical Recent Developments
  133. 6.23 Qilu Pharmaceutical
  134. 6.23.1 Qilu Pharmaceutical Company Information
  135. 6.23.2 Qilu Pharmaceutical Business Overview
  136. 6.23.3 Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Qilu Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  138. 6.23.5 Qilu Pharmaceutical Recent Developments
  139. 6.24 CSPC Ouyi Pharmaceutical
  140. 6.24.1 CSPC Ouyi Pharmaceutical Company Information
  141. 6.24.2 CSPC Ouyi Pharmaceutical Business Overview
  142. 6.24.3 CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 CSPC Ouyi Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  144. 6.24.5 CSPC Ouyi Pharmaceutical Recent Developments
  145. 6.25 Yangtze River Pharmaceutical
  146. 6.25.1 Yangtze River Pharmaceutical Company Information
  147. 6.25.2 Yangtze River Pharmaceutical Business Overview
  148. 6.25.3 Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Yangtze River Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  150. 6.25.5 Yangtze River Pharmaceutical Recent Developments
  151. 6.26 Chia Tai Tianqing Pharmaceutical
  152. 6.26.1 Chia Tai Tianqing Pharmaceutical Company Information
  153. 6.26.2 Chia Tai Tianqing Pharmaceutical Business Overview
  154. 6.26.3 Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Chia Tai Tianqing Pharmaceutical Direct Thrombin Inhibitors (DTIs) Product Portfolio
  156. 6.26.5 Chia Tai Tianqing Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Direct Thrombin Inhibitors (DTIs) Sales by Country
  2. 7.1.1 North America Direct Thrombin Inhibitors (DTIs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026)
  4. 7.1.3 North America Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Direct Thrombin Inhibitors (DTIs) Market Size by Country
  6. 7.2.1 North America Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026)
  8. 7.2.3 North America Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Direct Thrombin Inhibitors (DTIs) Sales by Country
  2. 8.1.1 Europe Direct Thrombin Inhibitors (DTIs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026)
  4. 8.1.3 Europe Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Direct Thrombin Inhibitors (DTIs) Market Size by Country
  6. 8.2.1 Europe Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country
  2. 9.1.1 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size by Country
  6. 9.2.1 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Direct Thrombin Inhibitors (DTIs) Sales by Country
  2. 10.1.1 South America Direct Thrombin Inhibitors (DTIs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026)
  4. 10.1.3 South America Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Direct Thrombin Inhibitors (DTIs) Market Size by Country
  6. 10.2.1 South America Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026)
  8. 10.2.3 South America Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country
  2. 11.1.1 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size by Country
  6. 11.2.1 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Direct Thrombin Inhibitors (DTIs) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Direct Thrombin Inhibitors (DTIs) Value Chain Analysis
  2. 12.1.1 Direct Thrombin Inhibitors (DTIs) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Direct Thrombin Inhibitors (DTIs) Production Mode & Process
  7. 12.2 Direct Thrombin Inhibitors (DTIs) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Direct Thrombin Inhibitors (DTIs) Distributors
  10. 12.2.3 Direct Thrombin Inhibitors (DTIs) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst